Treatments for Brain Metastases With Poor Prognostic Factors

Effects of Local and Systemic Treatments in Brain Metastases With Poor Prognostic Factors: Multicenter Retrospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05609162

Acronym

TBMPPF

Enrollment

2000

Registered

2022-11-08

Start date

2022-12-15

Completion date

2024-11-20

Last updated

2022-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastases

Keywords

Brain Metastases, local treatments, systemic treatments, poor prognosis

Brief summary

The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are: * What kind of local treatment provides a survival benefit for patients with poor prognostic factors? * What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors? * Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors? Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.

Interventions

PROCEDUREneurosurgical resection

neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Evidence of pathological diagnosis of primary tumor; 2. Brain metastases confirmed by enhanced magnetic resonance imaging; 3. Complete clinical information

Exclusion criteria

1. Survival time less than 30 days; 2. If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery; 3. Incomplete clinical data; 4. Patients with 2 or more types of tumors.

Design outcomes

Primary

Measure	Time frame	Description
OS	From date of first follow-up until the date of documented death from any cause, assessed up to 120 months	Overall survival time

Secondary

Measure	Time frame	Description
PFS	From date of first follow-up until the date of first documented progression, assessed up to 120 months	Progression-free survival time

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026